Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

9.350 -0.100 (-1.06%)
Streaming Delayed Price Updated: 1:42 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 178,645
Open 9.280
Bid (Size) 9.340 (300)
Ask (Size) 9.380 (200)
Prev. Close 9.450
Today's Range 9.225 - 9.560
52wk Range 8.250 - 50.40
Shares Outstanding 58,102,949
Dividend Yield 154.22%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week ↗
It failed to meet expectations for its final quarter of 2025. 
Via The Motley Fool
News headline image
Why Lenz Therapeutics Stock Crashed Today ↗
Is it time to throw away your reading glasses? Maybe not just yet. 
Via The Motley Fool

Performance

YTD
-41.6%
-41.6%
1 Month
-24.0%
-24.0%
3 Month
-42.7%
-42.7%
6 Month
-80.8%
-80.8%
1 Year
-49.0%
-49.0%

More News

Read More
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch ↗
Via Chartmill
News headline image
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings ↗
Via Benzinga
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics to Present at Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics to Present at Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q3 2025 Revenue Beat and Progress on VIZZ Launch ↗
Via Chartmill
News headline image
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation
Via MarketMinute
Topics Artificial Intelligence
News headline image
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is LENZ Therapeutics, Inc. - Common Stock publicly traded?
Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?
LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?
The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market
What is the current price of LENZ Therapeutics, Inc. - Common Stock?
The current price of LENZ Therapeutics, Inc. - Common Stock is 9.350
When was LENZ Therapeutics, Inc. - Common Stock last traded?
The last trade of LENZ Therapeutics, Inc. - Common Stock was at 04/09/26 01:42 PM ET
What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?
The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 543.26M
How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?
LENZ Therapeutics, Inc. - Common Stock has 543M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.